Intermuscular Coherence as a Biomarker for ALS
NCT05104710
This study is recruiting at 3 US sites in 3 states, according to its ClinicalTrials.gov record last updated .
Summary
The specific aims of this study are to: Determine if a painless and quick measurement of muscle activity using surface electrodes can help with the diagnosis of ALS. Specifically, we ask if a measure of intermuscular coherence (IMC-βγ), when added to current diagnostic criteria (Awaji criteria), can differentiate ALS from mimic diseases more accurately and earlier than currently possible. Characterize IMC-βγ in neurotypical subjects by age, sex, race, and ethnicity.
Shortened from the sponsor's brief summary. View official record on ClinicalTrials.gov
Conditions studied
- Amyotrophic Lateral Sclerosis
Eligibility basics and study details
- Study type
- Observational
- Phase
- Not applicable
- Ages
- 20 to 90 years
- Sex
- All
- Healthy volunteers
- Accepted
- Sponsor
- University of Chicago
- Last updated on ClinicalTrials.gov
- February 9, 2026
These are the basic criteria only. The full inclusion and exclusion criteria are on the official record, and the study team decides who can take part.
US recruiting sites
Florida · 1
- University of Miami Miller School of Medicine · Miami, FL
Massachusetts · 1
- Massachusetts General Hospital · Boston, MA
Missouri · 1
- Washington University Medical Center · St Louis, MO
Source: ClinicalTrials.gov, data processed . Recruiting US sites filtered by distance and site status; summaries shortened.